Medicine Advances最新文献

{"title":"Clarification to “Expert consensus on treatment for stage III non-small cell lung cancer”","authors":"","doi":"10.1002/med4.25","DOIUrl":"https://doi.org/10.1002/med4.25","url":null,"abstract":"<p>Wu YL, Lu S, Zhou QH, Zhang L, Cheng Y, Wang J, Wang BH, Hu CP, Lin LZ, Zhong WZ, Song Y, Yang N, Dong XR, Zhao J, Yang HH, Guo H, Yan XL, Liu HX, Ma R, Lin J, Liu SY, Chen C, Wang LF, Zhou CZ, Zhou M, Wu F, Yang XN, Du YY, Yao Y, Shao Y, Hong SD, Cui JW, Quan XP, Chen RR, Wu JY, Zhang JT, Zhou JY, Wang BC, Cheng C, Wang HJ, Liu JJ, Wu L, Huang Y, Kuang YK, Zhang YC, Hu J, Yang JJ, Feng WN, Su WM, Fan Y, Yang F, Chen M, Tang KJ, Tang Y, Shen P, Liu AW, Zhang HB, Liang WH, Zhou Q, Ma ZY, Cai XY, Liu H, Chen LF, Chuai SK, Chuai JZ, Zheng YF, You CX, Zhu XX, Li L, Zhang TM, Tu HY, Lin WR, Zhang XC, Zhou PH, Ke ZF, Liang HY. Expert consensus on treatment for stage III non-small cell lung cancer. Med. Adv. 2023;1:3–13.</p><p>We want to clarify that this article was originally published in Chinese in the <i>Journal of Evidence-based Medicine</i> (doi: 10.12019/j.issn.1671-5144.2022.03.001). This is an English translation of the original article and permission was granted by the <i>Journal of Evidence-based Medicine</i>.</p><p>The online version of the original article can be found at http://www.jebm.cn/CN/10.12019/j.issn.1671-5144.2022.03.001.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"171"},"PeriodicalIF":0.0,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.25","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50154001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complex interplay between the immune system, metabolism, and epigenetic factors in autoimmune liver diseases","authors":"Ya-Fei Xu,&nbsp;Zhi-Bin Zhao,&nbsp;Ethan P. Yan,&nbsp;Zhe-Xiong Lian,&nbsp;Weici Zhang","doi":"10.1002/med4.23","DOIUrl":"https://doi.org/10.1002/med4.23","url":null,"abstract":"<p>Autoimmune liver diseases (ALDs) are chronic inflammatory hepatobiliary diseases in which the autoimmune responses directed against liver tissue result in inflammation and tissue damage. There are several types of ALDs, including autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, immunoglobulin G4-related sclerosing cholangitis, and overlap syndromes. Metabolism and epigenetics are both critical components of the development and progression of ALDs. Immunometabolism addresses how metabolic processes influence immune cell development, fate and behavior, and how immune responses impact metabolism. In the context of immunity, epigenetics involves regulating gene expression without altering the DNA sequence. Epigenetic modifications can ultimately result in changes in the immunophenotype. The interplay between the immune system, metabolism, and epigenetic factors is highly complex. A better understanding of this interplay and the regulatory mechanisms involved is crucial to uncover the disease pathogenesis of ALDs and exploring novel therapeutic options. This article provides a comprehensive review of the dysregulation of immunometabolism and epigenetics, as well as the multilevel regulatory mechanisms, underlying the autoimmunity in ALDs.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"97-114"},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50140808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A glimpse of recent advances in the research of acute kidney injury","authors":"Zheng Dong,&nbsp;Xinling Liang","doi":"10.1002/med4.26","DOIUrl":"https://doi.org/10.1002/med4.26","url":null,"abstract":"<p>Acute kidney injury (AKI) is a major renal disease that affects 13 million people and is associated with almost 1.7 million deaths each year around the world. Previously referred to as acute renal failure, AKI is defined not only by a rapid functional decline of the kidney but also by pathological damages in kidney tissue. This updated definition contributes to modern renal medicine in at least two ways. First, the definition of AKI includes an early, preventable and treatable stage of the disease, which implies an urgent need for sensitive biomarkers for early diagnosis and treatment. Second, the AKI definition is proposed with clear criteria for diagnosis and severity grading, which are beneficial for clinical studies and the meta-analysis of different datasets.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"158-162"},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.26","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50141270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in incidence and mortality of acute kidney disease following coronary angiography in Chinese population: 2008–2017","authors":"Qiang Li,&nbsp;Haozhang Huang,&nbsp;Weihua Chen,&nbsp;Shanshan Shi,&nbsp;Xiaozhao Lu,&nbsp;Wenguang Lai,&nbsp;Guoxiao Liang,&nbsp;Jielan Wu,&nbsp;Jiyan Chen,&nbsp;Jin Liu,&nbsp;Shiqun Chen,&nbsp;Amanda Y. Wang,&nbsp;Yong Liu","doi":"10.1002/med4.20","DOIUrl":"https://doi.org/10.1002/med4.20","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute kidney disease (AKD) has received increasing attention owing to its poor prognosis. However, few studies have investigated the trends in AKD incidence and prognosis among patients undergoing coronary angiography (CAG). Therefore, this study was designed to explore trends in the incidence and mortality of AKD following CAG in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We enrolled patients undergoing CAG using data of the Cardiorenal Improvement (CIN) cohort registry of Guangdong Provincial People's Hospital. Univariate and multivariate logistic regression analyses were applied to examine the incidence of AKD from 2008 to 2017. Mortality rates are presented as deaths per 1000 person-years and were evaluated in univariate and multivariate Cox regression analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 9665 patients (mean age: 61.6 ± 9.6 years, 40% women) were enrolled in the final analysis. From 2008 to 2017, the overall incidence and mortality of AKD were 19% and 323.0 per 1000 person-years, respectively. The incidence of AKD decreased from 25% to 13% during 2008–2017 (adjusted odds ratio, 0.40; 95% confidence interval [CI], 0.31–0.51; <i>p</i> &lt; 0.01; <i>p</i> for trend &lt;0.01). However, the mortality of AKD increased significantly from 138.2 to 544.1 per 1000 person-years (adjusted hazard ratio, 2.85; 95% CI, 1.20–6.73; <i>p</i> = 0.02, <i>p</i> for trend = 0.02). The above trends were observed consistently in patients stratified by sex and age.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our findings suggest a significant decrease in incidence and an increase in mortality of AKD following CAG from 2008 to 2017 in China. We advocate for more proactive measures to prevent AKD and improve the prognosis of patients with AKD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"123-132"},"PeriodicalIF":0.0,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50152736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Generative Pre-Trained Transformer 4 in healthcare: Challenges, opportunities, and recommendations","authors":"Hassam Ali","doi":"10.1002/med4.21","DOIUrl":"https://doi.org/10.1002/med4.21","url":null,"abstract":"<p>GPT-4's advanced natural language processing capabilities can revolutionize patient education and clinical decision-making in healthcare, providing personalized and easily accessible content. Despite its potential, GPT-4's integration into healthcare raises important ethical and legal questions, particularly around data security, privacy, and transparency. To fully utilize GPT-4 in healthcare, further research, comprehensive regulations, and AI training in medical curricula are recommended.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"163-166"},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.21","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50129978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric investigation of undergraduate pharmacy education since the millennium via web of science","authors":"Zhengwei Huang,&nbsp;Rui Luo,&nbsp;Si Xiong,&nbsp;Chuanbin Wu,&nbsp;Xin Pan","doi":"10.1002/med4.15","DOIUrl":"https://doi.org/10.1002/med4.15","url":null,"abstract":"<p>The status quo of the current knowledge in pharmacy undergraduate education was figured out by bibliometric studies. Based on the current research hotspots, we proposed several suggestions for future directions.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"167-170"},"PeriodicalIF":0.0,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50139341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optical coherence tomography angiography features of retinal artery occlusion before and after intra-arterial thrombolysis","authors":"Qiaowei Wu,&nbsp;Yongyi Niu,&nbsp;Daiyu Chen,&nbsp;Hongbin Lin,&nbsp;Mingkui Tan,&nbsp;Yijun Hu,&nbsp;Honghua Yu,&nbsp;Anyi Liang","doi":"10.1002/med4.14","DOIUrl":"https://doi.org/10.1002/med4.14","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To evaluate the ability of optical coherence tomography angiography (OCTA) to quantitatively assess the effectiveness of intra-arterial thrombolysis (IAT) surgery for the treatment of retinal artery occlusion (RAO).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective observational study. Patients diagnosed with RAO who received IAT were enrolled. All participants underwent comprehensive ophthalmologic examinations and OCTA scans. The best-corrected visual acuity (BCVA), vascular densities (VDs) of the superficial capillary plexus (SCP), deep capillary plexus (DCP), radial peripapillary capillaries, and central retinal thickness (CRT) were recorded. The above parameters were compared between RAO eyes and the fellow healthy eyes before and after IAT. Correlations between the BCVA and OCTA parameters in RAO eyes were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four eyes from 34 consecutive RAO patients with a mean age of 51.0 ± 12.9 years were enrolled. There was a considerable decrease of VDs in the SCP, DCP, and radial peripapillary capillaries in all RAO eyes (all <i>p</i> &lt; 0.001). Compared with contralateral normal eyes, CRT was significantly increased in RAO eyes (<i>p</i> &lt; 0.001). The SCP and DCP VDs were significantly improved after IAT surgery (<i>p</i> = 0.010 and 0.014, respectively). BCVA in logMAR unit was negatively correlated with the DCP VD (<i>r</i> = −0.664, <i>p</i> = 0.010) and positively correlated with CRT (<i>r</i> = 0.597, <i>p</i> = 0.024) after surgery, but not significantly correlated with VDs or CRT before surgery.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Macular and peripapillary VDs of the retina detected by OCTA were greatly decreased in RAO eyes and improved after IAT treatment. OCTA is capable of quantifying VDs in separate retinal layers non-invasively, conveniently, efficiently, and precisely.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 2","pages":"115-122"},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50156143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on treatment for stage III non-small cell lung cancer","authors":"Yi-Long Wu,&nbsp;Shun Lu,&nbsp;Qinghua Zhou,&nbsp;Li Zhang,&nbsp;Ying Cheng,&nbsp;Jie Wang,&nbsp;Buhai Wang,&nbsp;Chengping Hu,&nbsp;Lizhu Lin,&nbsp;Wenzhao Zhong,&nbsp;Yong Song,&nbsp;Nong Yang,&nbsp;Xiaorong Dong,&nbsp;Jian Zhao,&nbsp;Haihong Yang,&nbsp;Hui Guo,&nbsp;Xiaolong Yan,&nbsp;Hongxu Liu,&nbsp;Rui Ma,&nbsp;Jie Lin,&nbsp;Siyang Liu,&nbsp;Chun Chen,&nbsp;Lifeng Wang,&nbsp;Chengzhi Zhou,&nbsp;Ming Zhou,&nbsp;Fang Wu,&nbsp;Xue-Ning Yang,&nbsp;Yingying Du,&nbsp;Yu Yao,&nbsp;Yang Shao,&nbsp;Shaodong Hong,&nbsp;Jiuwei Cui,&nbsp;Xueping Quan,&nbsp;Rongrong Chen,&nbsp;Jiayan Wu,&nbsp;Jiatao Zhang,&nbsp;Jianya Zhou,&nbsp;Binchao Wang,&nbsp;Chao Cheng,&nbsp;Huijuan Wang,&nbsp;Jingjing Liu,&nbsp;Lin Wu,&nbsp;Yan Huang,&nbsp;Yukun Kuang,&nbsp;Yongchang Zhang,&nbsp;Jia Hu,&nbsp;Jinji Yang,&nbsp;Weineng Feng,&nbsp;Wenmei Su,&nbsp;Yun Fan,&nbsp;Fan Yang,&nbsp;Ming Chen,&nbsp;Kejing Tang,&nbsp;Yi Pan,&nbsp;Peng Shen,&nbsp;Anwen Liu,&nbsp;Haibo Zhang,&nbsp;Wenhua Liang,&nbsp;Qing Zhou,&nbsp;Zhiyong Ma,&nbsp;Xiuyu Cai,&nbsp;Hui Liu,&nbsp;Longfei Chen,&nbsp;Shaokun Chuai,&nbsp;Jianzhen Shan,&nbsp;Yanfang Zheng,&nbsp;Changxuan You,&nbsp;Xiaoxia Zhu,&nbsp;Li Li,&nbsp;Tongmei Zhang,&nbsp;Haiyan Tu,&nbsp;Wurong Lin,&nbsp;Xuchao Zhang,&nbsp;Penghui Zhou,&nbsp;Zunfu Ke,&nbsp;Huiying Liang","doi":"10.1002/med4.7","DOIUrl":"https://doi.org/10.1002/med4.7","url":null,"abstract":"<p>Stage III non-small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Such patients should actively receive comprehensive treatments. It is imperative for all stage III NSCLC patients to receive consultation with a multiple disciplinary team, which allows the development of a proposal for clinical diagnosis and treatment. In this consensus, stage III NSCLC is divided into two types (operable and inoperable) according to different clinical conditions. Resectable NSCLC is further subdivided into two conditions (with or without driver genes). For each clinical scenario, this consensus emphasizes that the foundation of any medical decisions regarding the optimal diagnostic or therapy procedure is scientific evidence from clinical research. Finally, based on the level of evidence and strength of recommendations, this consensus provides recommendations for the management of stage III NSCLC from six perspectives. The objective of this consensus is to help clinicians choose the best treatment and promote the standardization of stage III NSCLC diagnosis and treatment in China.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 1","pages":"3-13"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of expert consensus on treatment for stage III non-small cell lung cancer","authors":"Weichi Luo,&nbsp;Riwei Zhong,&nbsp;Mingyi Yang,&nbsp;Qing Zhou","doi":"10.1002/med4.5","DOIUrl":"https://doi.org/10.1002/med4.5","url":null,"abstract":"<p>Stage III non-small cell lung cancer (NSCLC) encompasses a group of diseases with high heterogeneity. Currently, it is considered that both staging and optimal treatment of stage III NSCLC require the joint work of a multidisciplinary team (MDT) of expert physicians within the tumor committee. With the advent of precision therapy, targeted therapy and immunotherapy provide more novel options for patients with stage III NSCLC. However, the management of stage III NSCLC remains complex and controversial, with a myriad of potentially feasible options. At present, the management of stage III NSCLC does not satisfy medical needs, and consistent progress and breakthroughs are urgently needed in standardized diagnosis and treatment strategies. Moreover, the unique demographics of Chinese NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources [<span>1, 2</span>]. In view of the above situation, after in-depth communications and discussions, experts on lung cancer clinical research, transformational research, and basic research achieved consensuses about the multidisciplinary comprehensive treatment and biomarkers for resectable and unresectable stage III NSCLC at the 19th lung cancer summit and issued Expert Consensus on Treatment for Stage III Non-Small Cell Lung Cancer on June 15, 2022 [<span>3</span>].</p><p>The consensus provides recommendations in the following six respects: (1) Redefining the definition of “resectability”; (2) adjuvant targeted therapy for stage III NSCLC patients; (3) adjuvant immunotherapy for wild type stage III NSCLC; (4) selection of neoadjuvant or adjuvant therapy for stage III NSCLC patients; (5) treatment options for unresectable stage III NSCLC patients; and (6) translational research on molecular residual disease (MRD). Meanwhile, the level of evidence and strength of recommendations for this consensus are described in an easy-to-understand way and in line with international standards.</p><p>The consensus recommends adjuvant immunotherapy for driver mutation-negative patients with stage III NSCLC in line with NCCN guidelines, which is different in ASCO and ESMO guidelines [<span>4-6</span>]. The consensus recommends that adjuvant immunotherapy should be administered after the completion of postoperative chemotherapy and should be restricted to PD-L1-positive patients, preferably for patients with PD-L1 &gt; 50%. Stage III NSCLC patients who refuse adjuvant chemotherapy but have PD-L1 &gt; 50% can consider receiving adjuvant immunotherapy.</p><p>The previous guidelines only recommended immune checkpoint inhibitor (ICI) consolidation therapy after concurrent chemoradiotherapy for patients with stage III NSCLC. With the publication of GEMSTONE-301 trial, the consensus recommends ICI consolidation therapy not only after concurrent chemoradiotherapy but also after sequent","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 1","pages":"89-91"},"PeriodicalIF":0.0,"publicationDate":"2023-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing reveals distinct immune cell subsets in phalangeal and soft-tissue recurrence of giant cell tumor of bone","authors":"Meiling Yang,&nbsp;Fen Wang,&nbsp;Huishan Liang,&nbsp;Genxin Ji,&nbsp;Yating Lian,&nbsp;Changye Zou,&nbsp;Wei Zhao","doi":"10.1002/med4.10","DOIUrl":"https://doi.org/10.1002/med4.10","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Giant cell tumor of the bone (GCTB), an intermediate locally aggressive neoplasm that frequently involves the epiphyseal region of the long bones. GCTB of the distal phalanx and soft-tissue recurrences are extremely rare. Little is known about the cellular and molecular differences between GCTB of the long bones and rare sites.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We employed single-cell RNA sequencing to elucidate the transcriptional profiles of 28,992 cells originating from patients afflicted with GCTB in the femur, distal phalanx, and soft-tissue relapse. To confirm the critical findings, we subjected the paraffin sections of GCTB to immunohistochemical staining.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our study revealed that GCTBs in rare sites display distinct immune subtypes and antigen presentation gene signatures. We observed minimal lymphocyte infiltration in GCTBs of the phalanx. Further analyses demonstrated that the transforming growth factor-β pathway and profibrotic proteins were significantly upregulated in phalanx lesions. In contrast, GCTB cells from soft-tissue recurrence exhibited discernible chondrocyte characteristics but presented lower antigen-presenting ability compared to those from femur lesions. Notably, we identified an immunosuppressive subset of mast cells in the soft-tissue recurrence. The secretion of proangiogenic and immunosuppressive factors from these mast cells suggests their potential role in the formation of vascular-rich and immunosuppressive niches in recurrent lesions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Collectively, this study broadens our comprehension of the gene expression patterns observed in infrequent location GCTBs and furnishes a repository of information for illuminating promising therapeutic targets for rare GCTBs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"1 1","pages":"14-29"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50142184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}